The complaint filed against the NASDAQ-listed firm centers on violations of the Securities Exchange Act of 1934. According to court filings, ADMA Biologics allegedly issued false and misleading statements to the market, masking the true state of its financial health. Plaintiffs argue that the company artificially boosted its performance metrics, providing a distorted picture of its operational success during the specified period.
Investors target ADMA Biologics in new securities class action
Investors who purchased ADMA Biologics stock between August 9, 2024, and March 25, 2026, face a critical August 10 deadline to join a class action lawsuit. The litigation alleges the company misled shareholders by concealing related-party transactions and inflating sales figures through aggressive channel stuffing.
The DJS Law Group is currently soliciting participants for the suit, noting that shareholders do not need to be appointed as lead plaintiffs to recover potential losses. The firm, led by David J. Schwartz, specializes in securities litigation and is targeting August 10, 2026, as the final window for interested parties to come forward. Those affected by the share price fluctuations are encouraged to review their holdings and reach out to counsel to determine their eligibility for recovery.
Comments (0)
No comments yet. Be the first!